Corxel Pharmaceuticals, a clinical-stage biopharma company developing cardiometabolic treatments, raised a $287 million Series D1 round, it announced Thursday.
Why it matters: It's a notably large round for a cardiometabolic biotech — one of the industry's hottest sectors.
